June 25 (Reuters) - AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.

The ADJUVANT BR.31 Phase III trial did not meet the primary endpoint of disease-free survival versus placebo in early-stage non-small cell lung cancer after complete tumor removal in patients whose tumors express PD-L1 on 25% or more tumor cells, the drugmaker said.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)